India, Aug. 27 -- Shanghai Junshi Biosciences Co., Ltd. (1877.HK: 688180.SS), a biopharmaceutical company focused on innovative therapies, reported its interim results for the six months ended June 30, 2026.
The company highlighted higher revenue, a return to profitability, continued growth of toripalimab (TUOYI) sales, and progress across its oncology and immunology pipeline.
H1 Financial Highlights
The company reported profit attributable to owners of RMB 25.50 million, or RMB 0.02 per share compared with a loss of RMB 413.43 million, or RMB 0.42 in the prior-year period.
Junshi gained a H1 2026 revenue of RMB 1.69 billion, up 45% year-over-year from RMB 1.16 billion, primarily driven by higher pharmaceutical product sales.
Domestic ...